Initial Treatment of Polymyalgia Rheumatica

Recommended Initial Glucocorticoid Dosing

• The European League Against Rheumatism recommends starting prednisone at 12.5-25 mg daily as initial therapy for PMR, with most patients responding within 7 days 1
• The European League Against Rheumatism/American College of Rheumatology guidelines suggest tailoring the specific dose based on individual risk factors, with higher doses (20-25 mg) considered for patients at high risk of relapse and low risk of adverse events 1, 2
• The European League Against Rheumatism/American College of Rheumatology guidelines recommend lower doses (12.5-15 mg) for patients with diabetes, osteoporosis, glaucoma, or other glucocorticoid-related risk factors 1
• The European League Against Rheumatism strongly advises against initial doses >30 mg/day due to excessive adverse effects 1
• The European League Against Rheumatism discourages initial doses ≤7.5 mg/day as they provide insufficient anti-inflammatory effect 1, 3

Why Glucocorticoids Over NSAIDs

• The European League Against Rheumatism strongly recommends glucocorticoids instead of NSAIDs for PMR treatment, as glucocorticoids address the underlying inflammatory process, while NSAIDs provide only symptomatic relief 1, 2

Initial Tapering Schedule

• The European League Against Rheumatism recommends tapering to 10 mg/day within 4-8 weeks if symptoms are controlled 1
• The European League Against Rheumatism suggests reducing the dose by 1 mg every 4 weeks (or using alternating schedules like 10/7.5 mg on alternate days) once at 10 mg/day 1

Monitoring Requirements

• The European League Against Rheumatism recommends regular follow-up every 4-8 weeks during the first year to assess response and adverse effects 1
• The European League Against Rheumatism suggests documenting disease activity, inflammatory markers (ESR/CRP), and glucocorticoid-related adverse effects at each visit 1
• The European League Against Rheumatism recommends screening for comorbidities including hypertension, diabetes, osteoporosis, glaucoma, and infections 1

Managing Relapses

• The European League Against Rheumatism recommends increasing prednisone to the pre-relapse dose in case of a relapse 1, 4
• The European League Against Rheumatism suggests gradually decreasing the dose over 4-8 weeks back to the dose where relapse occurred 1, 4
• The European League Against Rheumatism recommends tapering more slowly than initially, not exceeding 1 mg per month 4

Adjunctive Measures

• The European League Against Rheumatism recommends assessment of cardiovascular risk factors and dyslipidemia for all patients 1
• The European League Against Rheumatology recommends patient education on disease course and self-monitoring 1
• The European League Against Rheumatism recommends direct access to healthcare providers for reporting flares or adverse events 1

Guideline Recommendations for Managing Metabolic and Bone Risks in Polymyalgia Rheumatica Patients on Prednisone

Blood‑Glucose Management

• A low‑glycemic‑index diet is recommended to minimize steroid‑induced hyperglycemia in patients receiving prednisone for PMR. 5
• Diabetes or glucose intolerance markedly increases the risk of glucocorticoid‑related adverse events, and such patients require careful metabolic monitoring during steroid therapy. 6

Bone Health & Exercise

• Engaging in weight‑bearing exercise for 30–60 minutes daily is a first‑line strategy to counteract prednisone‑associated bone loss in PMR. 5
• Patients should be offered individualized exercise‑program counseling to ensure safe and effective weight‑bearing activity. 5

Cardiovascular Risk Management

• Cardiovascular disease is a comorbidity that heightens the likelihood of glucocorticoid‑related adverse events; therefore, systematic assessment and management of cardiovascular risk factors (e.g., dyslipidaemia) are advised. 6

Monitoring & Follow‑up

• Regular clinical review every 4–8 weeks during the first year of prednisone therapy is recommended to evaluate bone health, blood‑glucose control, blood pressure, and other steroid‑related complications. 5
• Continuous documentation of steroid‑related side effects is essential to enable timely therapeutic adjustments. 5
• Monitoring should specifically include screening for osteoporosis, diabetes, hypertension, and other glucocorticoid‑induced complications. 6

Clinical Pitfalls

• Neglecting cardiovascular risk assessment can exacerbate the multiple metabolic disturbances caused by glucocorticoids beyond bone health. 6